Deal facts
- Buyer
- iBio, Inc.
- Target
- College Station Investors LLC
- Deal value
- USD 28,750,000
- Announced
- 4 November 2021
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash, shares
Sources
Weekly digest
Join Exit Mode Insider
Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.
Join Exit Mode Insider, £12/moDeal timeline
1 update- CompletedClosed
iBio, Inc. completes acquisition of College Station Investors LLC
Item 1.01. Entry into a Material Definitive Agreement. On November 1, 2021, iBio, Inc. (the “ Company ”) and its subsidiary, iBio CDMO LLC (“ iBio CDMO ”, and collectively with the Company, the “ Purchaser ”) entered into a series of agreements (the “ Transaction ”) with College Station Investors LLC (“ College Station ”), and Bryan Capital Investors LLC, each affiliates of Eastern Capital Limited
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.
Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.
- Buyer
- Shuttle Pharmaceuticals Holdings, Inc.
- Target
- United Dogecoin Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
MedPal AI plc to acquire Remedi Solutions Limited
MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.
- Buyer
- MedPal AI plc
- Target
- Remedi Solutions Limited
- Deal value
- GBP 310,000
- Deal type
- strategic acquisition
BIOMARIN PHARMACEUTICAL INC to acquire Amicus
BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.
- Buyer
- BIOMARIN PHARMACEUTICAL INC
- Target
- Amicus
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.
- Buyer
- Telomir Pharmaceuticals, Inc.
- Target
- TELI Pharmaceuticals, Inc.
- Deal value
- USD 34,389,710
- Deal type
- strategic acquisition
GSK plc to acquire 35Pharma Inc.
GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…
- Buyer
- GSK plc
- Target
- 35Pharma Inc.
- Deal value
- USD 950,000,000
- Deal type
- strategic acquisition
Buyer history
iBio, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive